Group 1 - The article discusses the significant stock movement of ProKidney (NASDAQ: PROK), which saw its share price increase from $0.6 to over $4.5 overnight, indicating strong market interest and potential catalysts driving this valuation change [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts, integrated financial statements, and market analysis for major pharmaceutical companies [1] - Edmund Ingham, a biotech consultant with over five years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma sectors [1]